Epinephrine self-injectable - kaleo

Drug Profile

Epinephrine self-injectable - kaleo

Alternative Names: Allerject; Auvi-Q; e-cue

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intelliject
  • Developer kaleo; Sanofi
  • Class Antiarrhythmics; Antihaemorrhagics; Antihypotensives; Bronchodilators; Catecholamines; Ethanolamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaphylaxis; Hypersensitivity

Most Recent Events

  • 27 Jul 2017 Epinephrine auto-injector receives priority review status for Anaphylaxis in USA
  • 27 Jul 2017 Kaléo files sNDA for epinephrine auto-injector for the treatment of Anaphylaxis in USA before July 2017
  • 23 Feb 2016 Sanofi and kaleo will terminate the license and development agreement by the end of 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top